11-19-03

Express Mail Label No.: EV312715325US

Date of Deposit: November 18, 2003

oel No.: EV312715325US
November 18, 2003

Attorney Docket No. 22596-531

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

The Content of the Krass

Attorney Docket No. 22596-531

Attorney Docket No. 22596-531

Nov 2 1003

The Content of the Krass

APPLICANTS:

SERIAL NUMBER:

FILING DATE:

October 10, 2001

ART UNIT:

1614

For:

PHARMACEUTICAL COMPOSITIONS CONTAINING B-LAPACHONE,

OR DERIVATIVES OR ANALOGS THEREOF, AND METHODS OF

USING SAME

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

TRANSMITTAL LETTER

Transmitted herewith for filing in the above-referenced patent application are the following documents:

- 1. Amendment and Response to August 18, 2003 Office Action (12 pgs.); and
- 2. Return Postcard.

The Commissioner is hereby authorized to charge any additional fees that may be due, or credit any overpayment of same, to Deposit Account No. 50-0311, Attorney Reference No. 22596-531. Should any questions or issues arise concerning this application, the Examiner is encouraged to contact the undersigned at the telephone number provided below.

Respectfully submitted,

November 18, 2003

Ivor R. Elrifi, Reg. No. 39,529

Attorneys for Applicants

c/o MINTZ, LEVIN Tel: (617) 542-6000 Fax: (617) 542-2241

Customer No.:30623

TRA 1854003v1

Express Mail Label No.: EV 312715325 US Date of Deposit: November 18, 2003

Attorney Docket No. 22596

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RADE RPPLICANT(S): Jiang et al.

> SERIAL NO.: 09/975,776

EXAMINER:

Frederick F. Krass

FILING DATE:

October 10, 2001

ART UNIT:

1614

For:

1.22596-50.
1.22596-50.
1.22596-50.
1.22596-50.
1.22596-50.
1.22596-50.
1.22596-50.
1.22596-50.
1.22596-50.
1.22596-50.
1.22596-50.
1.22596-50.
1.22596-50.
1.22596-50.
1.22596-50.
1.22596-50.
1.22596-50.
1.22596-50.
1.22596-50.
1.22596-50.
1.22596-50.
1.22596-50.
1.22596-50.
1.22596-50.
1.22596-50.
1.22596-50.
1.22596-50.
1.22596-50.
1.22596-50.
1.22596-50.
1.22596-50.
1.22596-50.
1.22596-50.
1.22596-50.
1.22596-50.
1.22596-50.
1.22596-50.
1.22596-50.
1.22596-50.
1.22596-50.
1.22596-50.
1.22596-50.
1.22596-50.
1.22596-50.
1.22596-50.
1.22596-50.
1.22596-50.
1.22596-50.
1.22596-50.
1.22596-50.
1.22596-50.
1.22596-50.
1.22596-50.
1.22596-50.
1.22596-50.
1.22596-50.
1.22596-50.
1.22596-50.
1.22596-50.
1.22596-50.
1.22596-50.
1.22596-50.
1.22596-50.
1.22596-50.
1.22596-50.
1.22596-50.
1.22596-50.
1.22596-50.
1.22596-50.
1.22596-50.
1.22596-50.
1.22596-50.
1.22596-50.
1.22596-50.
1.22596-50.
1.22596-50.
1.22596-50.
1.22596-50.
1.22596-50.
1.22596-50.
1.22596-50.
1.22596-50.
1.22596-50.
1.22596-50.
1.22596-50.
1.22596-50.
1.22596-50.
1.22596-50.
1.22596-50.
1.22596-50.
1.22596-50.
1.22596-50.
1.22596-50.
1.22596-50.
1.22596-50.
1.22596-50.
1.22596-50.
1.22596-50.
1.22596-50.
1.22596-50.
1.22596-50.
1.22596-50.
1.22596-50.
1.22596-50.
1.22596-50.
1.22596-50.
1.22596-50.
1.22596-50.
1.22596-50.
1.22596-50.
1.22596-50.
1.22596-50.
1.22596-50.
1.22596-50.
1.22596-50.
1.22596-50.
1.22596-50.
1.22596-50.
1.22596-50.
1.22596-50.
1.22596-50.
1.22596-50.
1.22596-50.
1.22596-50.
1.22596-50.
1.22596-50.
1.22596-50.
1.22596-50.
1.22596-50.
1.22596-50.
1.22596-50.
1.22596-50.
1.22596-50.
1.22596-50.
1.22596-50.
1.22596-50.
1.22596-50.
1.22596-50.
1.22596-50.
1.22596-50.
1.22596-50.
1.22596-50.
1.22596-50.
1.22596-50.
1.22596-50.
1.22596-50.
1.22596-50.
1.22596-50.
1.22596-50.
1.22596-50.
1.22596-50.
1.22596-50.
1.22596-50.
1.22596-50.
1.22596-50.
1.22596-50.
1.22596-50.
1.22596-50.
1.22596-50.
1.22596-50.
1.22596-50.
1.22596-50.
1.22596-50.
1.22596-50.
1.22596-50.
1.22596-50.
1.22596-50.
1.22596-50.
1.22596-50.
1.22596-50.
1.2259 PHARMACEUTICAL COMPOSITIONS CONTAINING β-LAPACHONE,

OR DERIVATIVES OR ANALOGS THEREOF, AND METHODS OF USING

SAME

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

AMENDMENT AND RESPONSE TO AUGUST 18, 2003 OFFICE ACTION

This paper is in response to the August 18, 2003 Office Action. A response is due on or before November 18, 2003. Applicants believe no additional fees are due with this response. However, the Commissioner is hereby authorized to charge any fees that may be due, or credit any overpayment of same, to Deposit Account No. 50-0311, Reference No. 22596-531.

Amendments to the Claims are reflected in the listing of claims which begins on page 2 of this paper.

Remarks are shown starting on page 9 of this paper.